All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering Committee About Us Newsletter Contact

Visit:

You're logged in! Click here any time to manage your account or log out.

Steering Committee About Us Newsletter Contact

DONATE

Brought to you by

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Ipsen Biopharmaceuticals, Lilly, and Pfizer. View funders.

Subtypes Therapeutics Congresses Trials Expert Opinions Educational Resources DRUG UPDATES

Lymphoma & CLL Subtypes

2019-06-26T13:44:27.000Z

ICML 2019 | How will front-line use of polatuzumab vedotin influence patient outcomes in DLBCL?

By Iqra Farooq, Hervé Tilly

Featured

Hervé Tilly

Jun 26, 2019

Bookmark this article

During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Hervé Tilly from CLCC Henri Becquerel, Rouen, FR, about how front-line use of polatuzumab vedotin might influence patient outcomes in diffuse large B-cell lymphoma (DLBCL).

Hervé Tilly describes how the study investigated the compound in combination with R-CHOP, and how the response rate of 89%, manageable safety profile, and a 77% complete response rate led to the proposal of an international, multi-center, double-blind, randomized phase II trial to compare the combination of R-CHOP and polatuzumab in 875 patients.

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

Thank you for rating this video.